ELIQUIS (apixaban), oral anticoagulant

• ELIQUIS has Marketing Authorisation in adults in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of their recurrence.
• Its short-term efficacy (6 months) was non-inferior to that of enoxaparin/warfarin in the initial treatment of DVT and PE after a first episode, which is most often idiopathic, with a lower risk of haemorrhage.
• Its long-term efficacy (12 months) versus placebo has been demonstrated in the prevention of recurrence of DVT and EP and of deaths of any cause, with no evidence of an increase in the risk of haemorrhage.
• There is no available means of monitoring the degree of anticoagulation achieved by the product and no antidote -available in case of need for rapid interruption of the anticoagulant effect.

-